Clinical Trial Detail

NCT ID NCT02141477
Title Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

bone marrow cancer

Therapies

Decitabine + Omacetaxine mepesuccinate

Age Groups: senior

No variant requirements are available.